Location: Solmed Polyclinic (Zagreb)
Study Drug: Experimental drug containing a GLP-1 agonist and an amylin analog, expected to have a stronger effect on glycemic control and weight reduction compared to the GLP-1 agonist alone.
Main Inclusion Criteria: Patients aged 18 and older with type 2 diabetes and excessive body weight (BMI > 25), who, with metformin therapy (with or without SGLT-2 inhibitors), have poorly controlled diabetes (HbA1c > 7.0%).
Status: Enrolling patients
Expected Start of Patient Enrollment: November 2023
Planned completion of new patient enrollment: April 2024
